Extracellular vesicles in vascular cognitive impairment and dementia: a neurovascular evidence map for patient stratification and clinical translation
- 1College of Clinical Medicine, Qinghai University
- 2Department of Geriatrics, Affiliated Hospital of Qinghai University
Abstract
Vascular cognitive impairment and dementia (VCID) comprises distinct syndromes caused by cerebrovascular injury and mixed vascular-neurodegenerative pathology. Extracellular vesicles (EVs), including small EV-enriched preparations, are being investigated as biomarkers and therapeutic products. We performed a structured narrative review and an expanded PubMed search through 8 October 2026, incorporating exosome, microvesicle and microparticle terminology. The revision search retrieved 140 records; representative evidence tables summarize 13 preclinical therapeutic studies and 10 human biomarker studies. We organize the evidence by EV preparation, neurovascular unit mechanism, clinical phenotype and development pathway. Therapeutic evidence remains predominantly preclinical. Human studies include exploratory cohorts and studies with separate validation datasets or longitudinal follow-up, but prospective clinical utility remains unestablished. Differences in EV separation, characterization, purity and cellular attribution limit cross-study comparison. We propose five evidence domains covering biological rationale, technical control, phenotype-relevant translation, clinical validation and prospective evaluation. This author-developed map integrates existing EV, biomarker and VCID development principles. It has not undergone consensus development, inter-rater reliability testing or prospective validation, and does not assign readiness scores or mandate sequential progression. Its intended use is to make evidence gaps explicit and connect candidate assays or products to defined patient populations, outcomes and safety requirements.
Related
- Animal models for investigating post-stroke cognitive impairment: A neurovascular trafficking perspective.
- Downregulation of Trpv4 and Klf2 in brain microvessels is associated with the progression of neurovascular dysfunction and cognitive impairment in a model of heart failure with preserved ejection fraction
- Modified Dioscorea pills ameliorate cognitive impairment induced by chronic cerebral hypoperfusion via restoring the hippocampal neurovascular unit
- Extracellular vesicle miRNAs, NOS/NO homeostasis, and NLRP3 inflammasome signaling in schizophrenia-related cognitive impairment: a mechanistic review and testable hypothesis
- Mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation-associated cognitive impairment and hippocampal microglial-synaptic remodeling
BibTeX
@article{li2026extracellular,
title = {{Extracellular vesicles in vascular cognitive impairment and dementia: a neurovascular evidence map for patient stratification and clinical translation}},
author = {Siqi Li and Junli Liu},
journal = {Frontiers in Neurology},
year = {2026},
month = oct,
doi = {10.3389/fneur.2026.1986081},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1986081/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Extracellular vesicles in vascular cognitive impairment and dementia: a neurovascular evidence map for patient stratification and clinical translation
AU - Siqi Li
AU - Junli Liu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1986081
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1986081/full
AB - Vascular cognitive impairment and dementia (VCID) comprises distinct syndromes caused by cerebrovascular injury and mixed vascular-neurodegenerative pathology. Extracellular vesicles (EVs), including small EV-enriched preparations, are being investigated as biomarkers and therapeutic products. We performed a structured narrative review and an expanded PubMed search through 8 October 2026, incorporating exosome, microvesicle and microparticle terminology. The revision search retrieved 140 records; representative evidence tables summarize 13 preclinical therapeutic studies and 10 human biomarker studies. We organize the evidence by EV preparation, neurovascular unit mechanism, clinical phenotype and development pathway. Therapeutic evidence remains predominantly preclinical. Human studies include exploratory cohorts and studies with separate validation datasets or longitudinal follow-up, but prospective clinical utility remains unestablished. Differences in EV separation, characterization, purity and cellular attribution limit cross-study comparison. We propose five evidence domains covering biological rationale, technical control, phenotype-relevant translation, clinical validation and prospective evaluation. This author-developed map integrates existing EV, biomarker and VCID development principles. It has not undergone consensus development, inter-rater reliability testing or prospective validation, and does not assign readiness scores or mandate sequential progression. Its intended use is to make evidence gaps explicit and connect candidate assays or products to defined patient populations, outcomes and safety requirements.
SN - 1664-2295
ER -